PRAG1 Antibody / Pragmin / PEAK1-related kinase-activating pseudokinase 1, 100 ug

PRAG1 antibody detects PEAK1-related, actin-binding guanine nucleotide exchange factor, also called Pragmin, a cytoskeletal and signaling adaptor involved in focal adhesion dynamics, actin organization, and cell migration. Encoded by the PRAG1 gene on chromosome 8q24.3, this multidomain protein acts as a nonreceptor tyrosine kinase scaffold that integrates signals from growth factor receptors and integrins to regulate cytoskeletal remodeling and motility. PRAG1 plays an important role in developmental morphogenesis and cancer cell invasion.

Structurally, PRAG1 contains an N-terminal actin-binding domain, a proline-rich region that interacts with SH3 domain-containing proteins, and multiple tyrosine phosphorylation motifs that recruit Src family kinases. Although it lacks intrinsic kinase activity, PRAG1 serves as a platform that enhances activation of FAK, Src, and downstream MAPK signaling, linking mechanical and biochemical cues during adhesion turnover. Its localization to focal adhesions and actin stress fibers reflects its role in maintaining cellular structure and migration capacity.

The PRAG1 antibody is widely used in cancer, developmental biology, and cytoskeletal signaling research to investigate adhesion signaling, actin dynamics, and metastatic potential. Western blot analysis detects a 170 kilodalton band corresponding to PRAG1, while immunofluorescence shows peripheral staining at focal adhesion sites and along actin filaments. This antibody supports studies examining integrin-mediated signaling and tumor cell invasion mechanisms.

Aberrant expression of PRAG1 contributes to epithelial-mesenchymal transition (EMT), tumor metastasis, and angiogenesis. Elevated PRAG1 levels enhance migration and invasion by promoting FAK/Src complex activation and actin remodeling. Conversely, depletion of PRAG1 suppresses motility and reduces metastatic spread. The PRAG1 antibody provides an essential tool for dissecting these molecular pathways and evaluating PRAG1 as a potential therapeutic target in oncology. NSJ Bioreagents validates this antibody for its applications, ensuring dependable detection in signaling and cytoskeletal research.